ReviewInternational journal of molecular sciences2019
Glucagon Control on Food Intake and Energy Balance.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07713992 (Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide), which is not on this map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide: A Multicenter, Prospective, Randomized Controlled Trial (IIT)
Who cites it
41 citing papers in PubMed, 73 citations in OpenAlex.
- Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.Diabetes, obesity & metabolism · 2025Trial
- Acute feeding with almonds compared to a carbohydrate-based snack improves appetite-regulating hormones with no effect on self-reported appetite sensations: a randomised controlled trial.European journal of nutrition · 2023Trial
- A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Postprandial Glucagon Action in the Human Brain.Diabetes, obesity & metabolism · 2026Article
- Hypothalamus-liver talks: whispers in the language of metabolism.Reviews in endocrine & metabolic disorders · 2026Review
- The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications.The Journal of clinical investigation · 2026Review
- Specific Glucagon Assay System Using a Receptor-Derived Glucagon-Binding Peptide Probe.International journal of molecular sciences · 2026Article
- Role of central and peripheral serotonin in liver physiology and diseases.Theranostics · 2026Review
- GLP1 receptor agonism alters growth and therapeutic response in prostate cancer.Endocrine-related cancer · 2025Article
- Adipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs.Current obesity reports · 2025Review
- Skeletal muscle growth to combat diabetes and obesity: the potential role of muscle-secreted factors.Obesity (Silver Spring, Md.) · 2025Review
- Glycogen homeostasis and mitochondrial DNA expression require motor neuron to muscle TGF-β/Activin signaling in Drosophila.iScience · 2025Article
- Side-Stream Based Marine Solubles From Atlantic Cod (Aquaculture nutrition · 2025Article
- Glucagon in metabolic disease: a mini-review of emerging multi-organ roles beyond glycemic control.Frontiers in endocrinology · 2025Review
- GLP-1 and GIP may play a role in long-term weight trajectories after gastric bypass.Frontiers in endocrinology · 2025Article
- Dogs fed a high protein, low carbohydrate diet have elevated postprandial plasma glucagon and amino acid concentrations and tend to have lower glucose concentrations compared to two different moderate protein, moderate carbohydrate diets.Translational animal science · 2025Article
- Medical Management of Obesity: Current Trends and Future Perspectives.Methodist DeBakey cardiovascular journal · 2025Review
- Glucagon receptor activation contributes to the development of kidney injury.American journal of physiology. Renal physiology · 2024Article
- Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care.Biomedicines · 2024Review
- Glycogen homeostasis and mtDNA expression require motor neuron to muscle TGFβ/Activin Signaling inbioRxiv : the preprint server for biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
Glucagon exerts pleiotropic actions on energy balance and has emerged as an attractive target for the treatment of diabetes and obesity in the last few years. Glucagon reduces body weight and adiposity by suppression of appetite and by modulation of lipid metabolism. Moreover, this hormone promotes weight loss by activation of energy expenditure and thermogenesis. In this review, we cover these metabolic actions elicited by glucagon beyond its canonical regulation of glucose metabolism. In addition, we discuss recent developments of therapeutic approaches in the treatment of obesity and diabetes by dual- and tri-agonist molecules based on combinations of glucagon with other peptides. New strategies using these unimolecular polyagonists targeting the glucagon receptor (GCGR), have become successful approaches to evaluate the multifaceted nature of glucagon signaling in energy balance and metabolic syndrome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.